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ABSTRACT
Introduction: Type 2 diabetic patients suffering
from severe hyperglycemia are often assigned a
regimen involving multiple daily injections
(MDI) of insulin. If the glucose toxicity resolves,
the regimen can potentially be simplified, but
there are no guidelines for this, and many
patients are left on the MDI regimen. We aimed
to prospectively examine the safety and efficacy
of switching from MDI to once-daily IDegLira, a
fixed-ratio combination of insulin degludec and
liraglutide, in relatively well controlled
(HbA1c B 7.5%) subjects with type 2 diabetes
on a low total daily insulin dose (TDD).
Methods: 62 adults with type 2 diabetes (base-
line age 64.06 ± 10.24 years, HbA1c
6.42 ± 0.68%, BMI 33.53 ± 6.90 kg/m2, body
weight 93.81 ± 19.26 kg, TDD
43.31 ± 10.99 IU/day, insulin requirement
0.47 ± 0.13 IU/kg, duration of diabetes
10.84 ± 7.50 years, mean ± SD) treated with
MDI ± metformin were enrolled in our study.
Previous insulins were stopped and once-daily
IDegLira was started. IDegLira was titrated by
the patients to achieve a self-measured pre-
breakfast blood glucose concentration
of\ 6 mmol/L.
Results: After a mean follow-up period of
99.2 days, mean HbA1c had decreased by 0.30%
to 6.12 ± 0.65% (p\0.0001), body weight had
decreased by 3.11 kg to 90.70 ± 19.12 kg
(p\ 0.0001), and BMI had reduced to
32.39 ± 6.71 kg/m2 (p\ 0.0001). After
3 months of treatment, the mean dose of IDe-
gLira was 20.76 ± 6.60 units and the mean
insulin requirement had decreased to
0.23 ± 0.08 IU/kg. IDegLira ± metformin com-
bination therapy was found to be safe and
generally well tolerated. During the month
before the baseline visit, 28 patients (45%) had
at least one episode of documented or symp-
tomatic hypoglycemia, while only 6 (9.67%)
patients reported a total of 13 documented
episodes during the follow-up.
Conclusion: In everyday clinical practice,
switching from low-dose MDI to IDegLira in
patients with well-controlled type 2 diabetes is
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safe, may result in weight loss and similar or
better glycemic control, and substantially
reduces the insulin requirement. Simplifying
complex treatment regimens decreases treat-
ment burden and may improve adherence to
therapy.
Clinical Trial Number: NCT04020445.
Keywords: Deintensification; IDegLira;
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INTRODUCTION
Type 2 diabetic patients suffering from severe
hyperglycemia are often assigned a regimen
involving multiple daily injections (MDI) of
insulin. If the glucose toxicity resolves, the
regimen can potentially be simplified, but there
are no specific guidelines for this, and many
patients are left on the MDI regimen for years,
meanwhile a significant proportion of them
become overtreated (overtreatment is defined as
the application of a treatment even when the
potential harm of that treatment exceeds its
possible benefits) [1–4].
Patients with type 2 diabetes (T2D) who are
treated with hypoglycemic agents too aggres-
sively and have HbA1c values that are perma-
nently lower than the range recommended are
considered to be overtreated and overcon-
trolled. Overtreatment of T2D with hypo-
glycemic medications is potentially harmful,
especially in frail individuals who are elderly or
have comorbidities, because it may increase the
risk of adverse events such as hypoglycemia and
weight gain, it imposes an unnecessary treat-
ment burden on the patient, and it worsens
their quality of life. Many recent studies have
demonstrated that overtreatment is a common
but generally unrecognized problem across the
spectrum of patients with T2D [5–7]. Another
type of overtreatment is when well-controlled
T2D patients are using unnecessarily complex
regimens instead of simpler alternatives that
would ensure the same glycemic control with a
lower treatment burden.
Deintensification is the process of simplify-
ing, reducing, or completely withdrawing
medications in order to reduce the risk of
polypharmacy and associated adverse events. In
spite of the high rates of complex medication,
deintensification is relatively uncommon in
everyday clinical practice [8–10]. Unfortunately,
evidence-based strategies to prevent overtreat-
ment in people with T2D and to simplify MDI
regimens are scarce. Moreover, there are many
barriers to deintensification at the healthcare
professional, general public, and healthcare
system levels [11, 12].
A first step towards preventing the detri-
mental medical consequences of and the
impaired quality of life caused by overtreatment
would be to analyze follow-up trials that are
designed to evaluate the outcomes of treatment
simplification.
Fixed-ratio combinations (FRCs) consisting
of a long-acting basal insulin and a glucagon-
like peptide-1 receptor agonist (GLP-1-RA) rep-
resent a novel approach to insulin therapy. One
of these combinations, IDegLira, comprises a
second-generation long-acting basal insulin
analog (insulin degludec, 100 units/mL) and the
GLP-1-RA liraglutide (3.6 mg/dL). Compared to
basal-bolus therapy, IDegLira provides a similar
degree of glycemic control but a reduced risk of
hypoglycemia, and it has a beneficial effect on
body weight [13].
The purpose of the study reported in the
present paper was to prospectively examine the
safety and efficacy of switching from MDI to
once-daily IDegLira in relatively well controlled
(HbA1c B 7.5%) subjects with T2D using a low
total daily insulin dose (TDD).
METHODS
Trial Design and Participants
This was a prospective, single-arm clinical trial
of patients with T2D in a real-world setting. It
was conducted at the Diabetes Center of the
Be´ke´s County Central Hospital—Dr. Re´thy Pa´l
Member Hospital (Be´ke´scsaba, Hungary) from
January 2016 until 2019.
The T2D patients included in the study
were C 18 years old and had detectable random
nonfasting serum C-peptide levels (C 1.1 ng/
mL; normal range 1.1–4.1 ng/mL) and HbA1c
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B 7.5%, which was treated with MDI
(stable daily doses of insulin had been admin-
istered for at least for 90 days prior to the
baseline visit [BV]) ± metformin (MF) at a rela-
tively low TDD. At BV, low TDD was defined as
TDD B 70 IU/day and TDD B 0.6 IU/kg/day.
Clearly overinsulinized patients who had severe
or repeated symptomatic hypoglycemia during
the month before BV and had TDD B 70 IU/day
and 0.8[TDD[0.6 IU/kg/day were also
admitted to the study. As IDegLira is a relatively
costly medicine in Hungary even though it is
covered by health insurance, only patients who
accepted the expense involved were enrolled in
the study.
Exclusion criteria included type 1 diabetes,
treatment of T2D with any medication for dia-
betes other than insulin or metformin during
the 90 days before BV, active cancer, anemia
(hemoglobin\100 g/L), and acute or chronic
kidney disease with an estimated glomerular
filtration rate\30 mL/min/1.73 m2.
Procedures
At BV, previous insulins were stopped and once-
daily IDegLira was started at any time, inde-
pendent of meals, and repeated at approxi-
mately the same time each day. IDegLira was
started with 16 units (with each unit containing
1 unit of insulin degludec and 0.036 mg of
liraglutide) and patients titrated every 3 days
with 2 units in order to achieve a pre-breakfast
self-measured blood glucose (SMBG) range of
5–6 mmol/L [14]. The maximum daily dose of
IDegLira was 50 units. Metformin was initiated
or continued and titrated up by 500 mg weekly
to 3000 mg or to the maximal tolerated dose.
Patients were asked to test blood glucose daily
in a structured manner (one measurement
before breakfast and one test before lunch or
dinner) and to record SMBG measurements in
their diaries.
Patients returned to the Diabetes Center
2 weeks after switching their therapy, at which
point their self-titration and adverse events
were rechecked (visit 0).
Patients were monitored over the course of
their routine medical care, and clinical
characteristics were assessed at baseline and
quarterly (every 3 months) after initiating IDe-
gLira. We present the results obtained at
3 months of IDegLira therapy (i.e., at visit 1) in
the present paper.
Outcome Measures
The primary endpoint was the change in HbA1c
from baseline to 3 months. Secondary outcomes
included changes in body weight, TDD, and
incidence of documented (SMBG\3.9 mmol/
L) or symptomatic episodes of hypoglycemia
after 3 months of treatment. Severe hypo-
glycemia requiring external assistance and
other clinically meaningful adverse events were
also monitored.
Statistical Analysis
Statistical analysis was performed using Graph-
Pad Prism 6 software (GraphPad Software, San
Diego, CA, USA). Data are presented as the
mean ± SD or the median with 25th and 75th
percentiles (interquartile range, IQR) for con-
tinuous variables with normal and non-normal
distributions, respectively, and as n (%) for fre-
quency data. Clinical and demographic vari-
ables measured before and after switching
therapy were compared using the two-tailed
paired t test for normally distributed data and
the Wilcoxon signed-rank test for non-normally
distributed data. p values\0.05 were consid-
ered to indicate statistically significant
differences.
Ethical Approval and Informed Consent
Our trial conformed to the recommendations of
the Declaration of Helsinki and the Interna-
tional Conference on Harmonisation Good
Clinical Practice norms with regard to medical
research in humans. The study protocol was
approved by the ethical review boards of the
institution and the Medical Research Council.
All patients provided a written informed con-
sent form before they were enrolled.
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RESULTS
Between February 2016 and July 2018, 69
T2DM patients meeting the trial’s inclusion
criteria were switched to IDegLira. Soon after
switching, 3 patients ceased the therapy for
financial reasons, 1 patient gradually reduced
and finally stopped IDegLira due to low SMBG
values before visit 1 and remained well con-
trolled on metformin monotherapy, 1 patient
discontinued the medication after a few days
due to moderate adverse gastrointestinal
effects, and 2 patients did not return to the
scheduled control. Thus, 62 patients (baseline
age 64.06 ± 10.24 years, HbA1c 6.42 ± 0.68%,
BMI 33.53 ± 6.90 kg/m2, body weight
93.81 ± 19.26 kg, TDD 43.31 ± 10.99 IU/day,
insulin requirement 0.47 ± 0.13 IU/kg, dura-
tion of diabetes 10.84 ± 7.50 years, mean ±
SD) attended an assessment 3 months after
initiating IDegLira (visit 1) and were included
in the analysis (Table 1).
At baseline, 49 (79%) patients were on a
basal-bolus regimen using 1 dose of basal insu-
lin and 3 doses of prandial insulin (38 used
human and 11 used an analog insulin), and 13
(21%) patients were treated with two or three
doses of human or analog premix insulins
(Fig. 1). At BV, 38 (61%) patients were taking MF
(median dose was 1500 [0–2000] mg), the mean
number of insulin injections daily was
3.69 ± 0.69, and the mean C-peptide was
4.00 ± 2.52 ng/mL.
After a mean follow-up of 99.2 days, HbA1c,
body weight, and BMI had decreased signifi-
cantly (Figs. 2, 3).
Mean HbA1c decreased by 0.30% to
6.12 ± 0.65% (p\0.0001), body weight
decreased by 3.11 kg to 90.70 ± 19.12 kg
(p\ 0.0001), and BMI decreased to
32.39 ± 6.71 kg/m2 (p\ 0.0001).
After 3 months of follow-up, the mean dose
of IDegLira was 20.76 ± 6.60 units (the mean
dose of liraglutide was 0.75 mg), the median
dose of metformin was 2000 [1000–2000] mg,
and the mean insulin requirement had
decreased to 0.23 ± 0.08 IU/kg.
IDegLira ? metformin combination therapy
was found to be safe and generally well toler-
ated. Transient gastrointestinal adverse events
Table 1 Patient characteristics at baseline and at 3 months of follow-up
Characteristic At baseline At 3 months
(visit 1)
Estimated mean difference
(95% CI)
p value*
HbA1c (%) 6.42 (0.68) 6.12 (0.65) - 0.30 (- 0.42 to - 0.18) p\ 0.0001
Body weight (kg) 93.81 (19.26) 90.70 (19.12) - 3.11 (- 4.04 to - 2.18) p\ 0.0001
BMI (kg/m2) 33.53 (6.90) 32.39 (6.71) - 1.14 (- 1.47 to - 0.81) p\ 0.0001
Total daily insulin dose (units) 43.31 (10.99) 20.76 (6.60) - 22.55 (24.96–20.14) p\ 0.0001
Insulin requirement (IU/kg) 0.47 (0.13) 0.23 (0.08) - 0.24 (- 0.27 to - 0.21) p\ 0.0001
Metformin dose (mg/day) 1500 [0–2000] 2000 [1000–2000] NA p\ 0.0001
Values are the mean (SD) or the median [IQR]
* From the Wilcoxon signed-rank test for metformin dose and the paired t test for other parameters
Fig. 1 Proportions of patients using different kinds of
insulin regimens at baseline
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(lack of appetite, nausea, or diarrhea) were
reported by 14 patients (22.5%), and 1 patient
had transient dysthymia. Only one serious
adverse event occurred (acute non-ST segment
elevation myocardial infarction), which in our
opinion was not related to the IDegLira therapy.
During the month before BV, 28 patients
(45%) had at least one episode of documented
(self-measured plasma glucose\ 3.9 mmol/L) or
symptomatic hypoglycemia, while only 6
(9.67%) patients reported a total of 13 docu-
mented (1 asymptomatic and 12 mild) episodes
during the follow-up. Severe hypoglycemia
requiring external assistance did not occur
(Fig. 4).
The mean daily number of injections chan-
ged from 3.69 to 1, and the patients reported a
substantial decrease in the number of blood
glucose tests performed each day.
The proportions of the patients who had
achieved HbA1c B 7% and HbA1c B 6.5% were
92% (n = 57) and 66% (n = 41), respectively
(Fig. 5). The proportions of the patients who
achieved HbA1c B 7% and HbA1c B 6.5% with-
out any weight gain were 79% (n = 49) and 53%
(n = 33), respectively. The proportions of the
patients who attained HbA1c B 7% and HbA1c
B 6.5% without hypoglycemia were 82.25%
(n = 51) and 56.45% (n = 35), respectively.
Finally, the proportions of the patients who
realized HbA1c B 7% and HbA1c B 6.5% with-
out weight gain and without hypoglycemia
were 72.58% (n = 45) and 46.77% (n = 29),
respectively.
DISCUSSION
MDI is recommended as an initial therapy when
blood glucose is C 16.7 mmol/L, HbA1c is
C 10%, or if symptoms of hyperglycemia (i.e.,
polyuria, polydipsia) are present [15]. The main
advantage of insulin over other glucose-lower-
ing medications is that it lowers glucose in a
dose-dependent manner over a wide range and
to almost any glycemic target. The most
important barrier to its glucose-lowering
potential is the risk of hypoglycemia in many
insulin regimens. As the patient’s glucose toxi-
city resolves, the complex regimen introduced
initially can potentially be simplified, but there
Fig. 2 HbA1c (mean ± SD) of the patients at baseline
and 3 months later
Fig. 3 Body weight (mean ± SD) of the patients at
baseline and 3 months later
Fig. 4 The percentage of patients experiencing at least one
episode of documented (self-measured blood glu-
cose\ 3.9 mmol/L) or symptomatic hypoglycemia during
the month before baseline visit (BV) was 45%, whereas the
corresponding percentage at the 3-month follow-up was
9.67%
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are no guidelines for medication deintensifica-
tion and many patients are overtreated with
MDI for years [1–3]. Overtreatment can also
occur when T2D patients achieve long-term
glycemic control within the target range with
an excessively complex insulin regimen. This
results in a significant treatment burden and a
worse quality of life than achieved with simpler
alternatives that permit the same glycemic
control.
Clinical practice guidelines have long
focused on intensifying therapy to achieve tar-
get HbA1c levels soon after diagnosis. Treatment
intensification currently involves the stepwise
addition of new non-insulin glucose-lowering
agents, the initiation of an insulin, or a switch
to a more complex insulin regimen. Long-term
intensive glucose control can reduce the risk of
diabetes-associated microvascular complica-
tions, but the type of treatment and the
patient’s condition play decisive roles in the
success of the therapy. The application of an
intensive but complex insulin therapy in older
patients with several associated comorbidities
might lead to perfect HbA1c levels but it may
also increase the risks of hypoglycemia and
weight gain [5, 16]. This kind of overtreatment
is detrimental to most patients [17]. In line with
this, the latest guidelines recommend the
deintensification of treatment regimens in older
adults [3]. It is also generally accepted that older
and younger patients are being overtreated if
they are treated too aggressively and their
HbA1c values are permanently below their
individually defined target ranges. Recent stud-
ies suggest that overtreatment is a common and
generally unrecognized problem among
patients with T2D, but rates of medication
deintensification in everyday clinical practice
are low, and evidence-based strategies for pre-
venting overtreatment and simplifying therapy
are yet to be devised [5–9]. In general, treatment
deintensification in T2D involves dosage
reduction, the discontinuation of a medication,
and the simplification of a complex regimen.
A few studies of a small number of older T2D
patients treated with hypoglycemic medica-
tions have examined the outcomes of deinten-
sification regimens, but there are no published
data on the process of simplifying complex
insulin regimens in patients with well-con-
trolled diabetes [12]. The aim of our real-world
prospective study was to examine the safety and
efficacy of switching from MDI to once-daily
IDegLira in relatively well-controlled (HbA1c
B 7.5%) subjects with T2DM using a low TDD.
At baseline, most of the patients using complex
insulin regimens who were enrolled in our
study had optimal glycemic control. Medica-
tion simplification was performed in those cases
to decrease treatment burden and improve
quality of life. However, as some of our patients
Fig. 5 Proportions of patients who had achieved various glycemic targets at visit 1
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had HbA1c values that were too low, leading to a
high risk of hypoglycemia, reducing the fre-
quency of hypoglycemia and achieving appro-
priate glycemic control were also objectives.
The results of a study of elderly T2D patients
(n = 65) with one or more episodes of hypo-
glycemia detected with continuous glucose
monitoring (CGM) showed that switching MDI
to a single dose of basal insulin (glargine U100)
can decrease the risk of hypoglycemia and dis-
ease-related distress without compromising
glycemic control [11]. In our study, instead of a
single long-acting basal insulin, we used IDe-
gLira (a fixed-ratio combination of a long-acting
basal insulin and a GLP-1 RA) for medication
deintensification because it has been demon-
strated that IDegLira produces a significantly
greater improvement in overall glycemic con-
trol than a basal insulin (due to the fasting and
prandial effects of liraglutide) as well as a sig-
nificantly reduced frequency of hypoglycemia
and a more favorable effect on body weight
[18, 19]. Compared to high-dose monotherapies
of the two components, we use lower doses of
both degludec and liraglutide in the fixed-ratio
combinations, which can result in lower risk of
adverse effects.
Other works in the literature also encouraged
us to use IDegLira to simplify MDI. For instance,
the DUAL VII trial demonstrated that IDegLira
exerts comparable glycemic effects to MDI on
patients with uncontrolled T2DM who are on
glargine U100 plus metformin. That trial
showed that IDegLira provided lower hypo-
glycemia rate and weight loss versus weight
gain compared to MDI treatment. In addition,
the cardiovascular outcome trials LEADER and
DEVOTE confirmed the cardiovascular benefits
and safety of liraglutide and degludec
[13, 20, 21].
As C-peptide is a widely used measure of
pancreatic beta-cell function, we only included
patients with detectable levels of this marker in
our study. C-peptide is produced in equimolar
amounts to endogenous insulin but is excreted
at a more consistent rate over a longer period
[22].
One of the descriptive parameters analyzed
in our study was TDD. The average daily insulin
production of healthy men is about 0.7–0.8 IU/
kg. Mean TDD in T2DM can vary considerably
with the level of insulin resistance and beta-cell
function, but Caucasian patients treated with
MDI regimens usually have TDDs between 0.9
and 1.4 unit/kg [13, 23, 24]. We supposed that a
normal or near-normal HbA1c achieved with a
low TDD is associated with some degree of
preserved endogenous insulin secretion. We
defined a low insulin requirement as an average
TDD B 0.6 IU/kg of body weight, and used this
definition together with the C-peptide level to
identify potential candidates for our study.
Despite the low baseline TDD, the combined
application of liraglutide and degludec resulted
in a further reduction in TDD and maintenance
of an excellent glycemic control.
There are two main explanations for the
insulin-sparing effects of liraglutide. On the one
hand, liraglutide has a strong glucose-lowering
effect deriving from the glucose-dependent
enhancement of insulin secretion and the
inhibition of glucagon secretion. On the other
hand, substantial weight loss is associated with
liraglutide treatment, leading to a lower insulin
requirement. The safety of our patients was
ensured by the study design, as the maximum
daily dose of IDegLira was 50 units, and we only
enrolled patients with TDD B 70 units/day at
BV in order to recover from the effects of the
previous complex regimen. The therapeutic
success of deintensification was observed in
other parameters aside from the halved mean
insulin requirement and the mean loss of 3 kg
in body weight. Although the baseline glycemic
control was acceptable, there was a further
reduction in mean HbA1c and the hypo-
glycemia risk had decreased substantially at the
3-month follow-up visit. The benefits of dein-
tensification are emphasized by the fact that, at
the follow-up visit, 92% of our patients had
HbA1c B 7%, and 72% had reached that target
without weight gain or hypoglycemia.
According to our observations,
IDegLira ? metformin combination therapy is
safe and generally well tolerated. Transient non-
serious gastrointestinal adverse events (lack of
appetite, nausea, or diarrhea) were reported by
14 patients (22.5%), and 1 patient had transient
dysthymia. The incidence, severity, and tran-
sient nature of these digestive symptoms were
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similar to those reported in another study of
T2DM patients on IDegLira [13]. In our study,
only one serious adverse event occurred during
the follow-up period (acute non-ST segment
elevation myocardial infarction), which in our
opinion was not related to the IDegLira therapy.
One of our aims was to describe the charac-
teristics of well-controlled T2D patients who are
treated with MDI but are eligible for medication
simplification, and we wished to demonstrate
the feasibility of switching MDI to IDegLira in
those patients in everyday clinical practice. The
results of our study demonstrated that complex
insulin regimens can be simplified in adult T2D
patients who have HbA1c B 7.5%, are being
treated with low-dose (TDD B 0.6 IU/kg and
TDD B 70 IU/day) MDI, and have a
detectable (C 1.1 ng/mL) random non-fasting
serum C-peptide level, indicating that there is
some endogenous insulin secretion. We were
looking for well-controlled patients, but we
found that some of our enrolled patients were
overcontrolled, as they were treated too
aggressively and had HbA1c values below the
target range, leading to a high risk of
hypoglycemia.
According to our results measuring HbA1c,
C-peptide and calculating the TDD can help
clinicians to identify well-controlled but over-
treated patients who would benefit from medi-
cation deintensification. We showed that it is
feasible to switch MDI to IDegLira, as the ini-
tially overtreated patients in our study achieved
similar or better HbA1c values, had fewer epi-
sodes of hypoglycemia, lost weight, and per-
formed only one injection daily with IDegLira
upon switching from their previous complex
insulin regimens. Our observations support the
notion that combined liraglutide–degludec
treatment has long-term benefits over MDI
therapy. The achievement of the target HbA1c
lowers the risk of microvascular complications,
and the weight loss observed to occur with
IDegLira complements its beneficial effects on
insulin sensitivity. Furthermore, the need to
inject only once rather than 2–4 times daily and
the reduced risk of hypoglycemia when using
IDegLira appreciably improves quality of life
and adherence to therapy.
Our prospective before–after study per-
formed in a real-world setting does, however,
have several limitations. It was a nonrandom-
ized, nonblinded, uncontrolled, single-center
study. Besides switching to IDegLira, the titra-
tion of metformin also affected the HbA1c effi-
cacy, but we could not estimate the strength of
that effect. It is also possible that in the patients
who were treated with human insulin, switch-
ing to a second-generation analog basal insulin
could have resulted in a lower risk of hypo-
glycemia and better glycemic control. Also, the
follow-up period was rather short and the sam-
ple size was relatively small, which is why
enrollment is ongoing at our site—we wish to
confirm our results in a larger group of patients
and over a longer follow-up period.
CONCLUSION
Our preliminary data suggest that in everyday
clinical practice, switching well-controlled (or
overcontrolled) T2DM patients of different ages
from low-dose MDI to IDegLira is safe, leads to
similar or better glycemic control, substantially
reduces the insulin requirement, and may
induce weight loss. It should be noted that this
approach may, however, be associated with
transient digestive symptoms.
Simplifying complex treatment regimens
decreases treatment burden and may improve
adherence.
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